Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
Now a test that offers new precision in prostate cancer detection
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Subscribe To Our Newsletter & Stay Updated
